General Information
Recombinant human c-Src and p38-α proteins were purchased from Abcam (Cat. No. ab79635, ab82188). Antibodies used for immunoblotting were purchased from Cell Signaling and LI-COR (Cat. No. CS #2109, CS#9218S, LI-COR 926-32211). Antibodies used for TR-FRET assay were purchased from Abcam (Ab31828, Ab170099, Ab16885, Ab109381). Tb-labeled secondary antibodies (LanthaScreen PV3774, PV3766) were purchased from Thermo-Fisher Scientific. Invitrogen PVDF membranes were used for immunoblots and scanned using Odyssey Imager. Solvents and chemicals were purchased from commercial sources and used directly without further purification. 1 H NMR spectra were recorded with Agilent 400-MR, Varian Inova 500 MHz, Varian VNMRS 500 MHz, Bruker Avance III 500 MHz. Chemical shifts were reported in ppm using either TMS or deuterated solvents as internal standards (TMS, 0.00; CDCl 3 , 7.26; CD 3 OD, 3.34; DMSO-d 6 , 2.50). Multiplicity was reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, brs = broad.
IED-DA ligation-based pull-down assay
30 million of K562 cells were plated in 5 mL of full media (IMDM + 10% FBS) and incubated with Dasatinib at the indicated concentration (1 µL of 5000x DMSO stock solution was added). After 1 h, cells were treated with probe 2 (1 µL of 10 mM DMSO stock solution). After 2 h cells were harvested, washed twice with 5 mL of PBS, and 250 µL of lysis buffer was added (lysis buffer: PBS, 0.02 % Tween, 100 mM NaCl, protease and phosphatase inhibitors, pH=7.4). Cells were subjected to sonication on ice for 20 s and subsequent centrifugation for 10 min at 14000 xg (4 °C). Supernatants were removed and Bradford analysis was performed to estimate total protein concentration. Lysates (20 µg of total protein was used per sample) were mixed with tetrazine-conjugated beads (60 µL). After 45 min incubation at 4 °C, beads were washed with ice cold lysis buffer (3x750 µL). Protein from enriched samples was eluted from beads with 50 µL of 2× LDS sample buffer (Invitrogen): 141 mM Tris base, 106 mM Tris HCl, 2% LDS, 10% glycerol, 0:51 mM EDTA, 0:22 mM SERVA Blue G, 0.175 mM Phenol Red pH 8.5 and kept at 80 °C for 10 minutes before being subjected to electrophoresis (15 µL per sample was loaded, 4-12% Bis-Tris SDS-PAGE and MOPS running buffer were used). Following immunoblot analysis was performed using iBlot transfer (Invitrogen), and c-Src and p38-α were visualized using commercial antibodies (CS #2109, CS#9218S, LI-COR 926-32211). Immunoblots were visualized on Odyssey Imager. Analysis of immunoblots was performed using Image Studio software.
Cellular TR-FRET assay
1.25 M cells in 100 µL/well of media were plated in 96-well plates and treated with Dasatinib at the indicated concentration (1 µL of 100x DMSO stock solution was added). After 1 h incubation, cells were treated with probe 3 (1 µL of 0.3 µM stock solution was added for the final concentration 3 nM). After 1 h, cells were harvested, washed three times with 200 µL of cold PBS +1% FBS and 100 µL of lysis buffer was added (0.1% NP40, 5 mM EDTA, 50 mM MgCl 2 , protease inhibitors, pH=7.4). Cells were incubated at RT for 30 min and 5 µL of lysate was transferred to 384-well white Proxi plates (Promega). 10 µL of kinase buffer A containing c-Src antibody (0.225 nM) (Ab16885, final concentration 0.15 nM) and 0.1 µg of Tb-labeled secondary antibody (LanthaScreen Tb-labeled Anti-rabbit, PV3774) was added. The mixture was incubated at RT. The measurements were conducted on Envision plate reader (Perkin-Elmer) over 24 hours.
Kinome profiling
Plates were stamped with 5 µL of kinase buffer (Life Technologies #PR4940D) containing recombinant kinase (2.5 -10 nM final concentration), Eu-or Tb-labeled antibodies (His or GST; 0.5-2 nM final concentration) and fluorescently-tagged probe (3-200 nM final concentration). Appropriate probes were diluted in kinase buffer and 120 µL of compound was added to the plate using Biomex FX. Plates were incubated at RT for 2 h and the measurements were conducted using Envision plate reader (Perkin-Elmer). The K i values were calculated using the Assay Explorer software (Accelrys). Example for BTK kinase: BTK (Invitrogen, PV3363) was added to 5 µL kinase buffer (Life Technologies, #PR4940D) to a final concentration of 10 nM, supplemented with 2 nM of Tb-labeled anti-His antibody and 200 nM Oregon Green labeled probe. Afterwards, 120 µL of diluted compound in kinase buffer was added and the plate was incubated at RT for 2 h. The measurements were conducted using Envision plate reader (Perkin-Elmer) and the K i values were calculated using the Assay Explorer software.
Cell proliferation assay
Dasatinib and all probes were profiled in K562 cell line according to reported Promega procedure:
https://www.promega.com/resources/protocols/technical-bulletins/0/celltiter-gloluminescent-cell-viability-assay-protocol/ 
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Synthesis of (1R,8S,9r,Z)-ethyl bicyclo[6.1.0]non-4-ene-9-carboxylate (2-a)
A solution of ethyl acrylate (20 g, 200 mmol) in 300 mL dichloromethane was added dropwise via syringe pump at 0 o C under a nitrogen atmosphere to a solution of (1Z,5Z)-cycloocta-1,5-diene (184 g, 1698 mmol) and tetrakis(acetato)dirhodium(II) (2 g, 4.53 mmol) in 300 mL dichloromethane. The resulting mixture was allowed to warm up and it was stirred for two days at room temperature. The mixture was filtered and concentrated under reduced pressure and the residue was purified by silica gel column chromatography using a gradient of petroleum ether: ethyl acetate 400:1 to 100:1 to afford the title compound (9 g, 46.3 mmol, 39.8 % yield) as a colorless oil. 1 
Synthesis of (1R,8S,E)-ethyl bicyclo[6.1.0]non-4-ene-9-carboxylate (2-b)
A Biotage / ISCO MPLC continuous flow apparatus was used for the photoisomerization reaction using a procedure previously reported, (1) with the following modification: two 120 g (Biotage SNAP cartridges) were used to house the silica gel and silver nitrate impregnated silica gel. One of the SNAP cartridges was filled with unmodified silica gel. The other SNAP cartridge contained a bed of unmodified silica gel that was topped with 100 g of silica gel which was impregnated with silver nitrite (20 g, 118 mmol). To the dried silica gel was sequentially added 28% ammonium hydroxide aqueous (500 mL) and dichloromethane (500 mL) and the resulting biphasic mixture was filtered. The filter cake was washed with additional dichloromethane (200 mL) and ammonium hydroxide (200 mL). The filtrate was transferred to a separatory funnel and partitioned. The aqueous layer was extracted with dichloromethane (300 mL). The organic layers were combined, washed twice with water (500 mL), dried with sodium sulfate, filtered and concentrated at 20 o C to give a residue, which was purified by column chromatography on silica gel, eluted with petroleum ether/ethyl acetate = 20/1) to afford the title compound (0.7 g, yield 23%) as colorless oil. 1 To a solution of (1R,8S,E)-ethyl bicyclo[6.1.0]non-4-ene-9-carboxylate (2-b) (0.7 g, 5.2 mmol) in methanol (20 mL) and water (8 mL) was added lithium hydroxide (0.6 g, 25.7 mmol). The mixture was stirred at 45°C for 3 hours. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was diluted with water (50 mL) and washed with methyl tert-butyl ether (3 × 30 mL). The aqueous phase was adjusted to pH = 4 with 0.5 M hydrochloride solution and then extracted with methyl tert-butyl ether (3 × 30 mL). Compound 2-i (8 mg, 0.016 mmol) and BODIPY-FL, SE (5 mg, 0.013 mmol, Invitrogen) were mixed in dimethylformamide (1 mL) with DIEA (N,N-diisopropylethylamine) (0.011 mL, 0.066 mmol). The reaction was stirred at room temperature overnight. The crude reaction mix was purified by reverse phase HPLC using a Gilson system and a C18 25 x 100 mm column, eluting with 5-85% acetonitrile in water containing 0.1% v/v trifluoroacetic acid. The product fractions were lyophilized to give the title compound as the TFA salt 
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